WO2003088949A3 - Matrix mit einer bioaktiven phospholipid-haltigen komponente - Google Patents

Matrix mit einer bioaktiven phospholipid-haltigen komponente Download PDF

Info

Publication number
WO2003088949A3
WO2003088949A3 PCT/EP2003/004030 EP0304030W WO03088949A3 WO 2003088949 A3 WO2003088949 A3 WO 2003088949A3 EP 0304030 W EP0304030 W EP 0304030W WO 03088949 A3 WO03088949 A3 WO 03088949A3
Authority
WO
WIPO (PCT)
Prior art keywords
matrix
component
component containing
containing phospholipid
bioactive component
Prior art date
Application number
PCT/EP2003/004030
Other languages
English (en)
French (fr)
Other versions
WO2003088949A2 (de
Inventor
Dirk Cremer
Elisabeth Markl
Original Assignee
Bioghurt Biogarde Gmbh & Co Kg
Dirk Cremer
Elisabeth Markl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10250727A external-priority patent/DE10250727B4/de
Application filed by Bioghurt Biogarde Gmbh & Co Kg, Dirk Cremer, Elisabeth Markl filed Critical Bioghurt Biogarde Gmbh & Co Kg
Priority to AU2003229693A priority Critical patent/AU2003229693A1/en
Priority to JP2003585701A priority patent/JP4599604B2/ja
Priority to US10/511,888 priority patent/US20050232996A1/en
Priority to EP03722502A priority patent/EP1503742A2/de
Publication of WO2003088949A2 publication Critical patent/WO2003088949A2/de
Publication of WO2003088949A3 publication Critical patent/WO2003088949A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Gegenstand der vorliegenden Erfindung ist eine Matrix mit einer bioaktiven, Phospholipid-haltigen Komponente, die aus 5 bis 98 Gew.-% Phosphatidylserin und 1 bis 90 Gew.-% Phosphatidylcholin besteht. Des Weiteren können 1 bis 94 Gew.-% einer Fett-Komponente pflanzlichen und/oder tierischen Ursprungs, einer Wachs-Komponente, einer Polyalkohol-Komponente und/oder weiterer physiologisch verträglicher Zusätze enthalten sein. Bevorzugt wird in diesem Zusammenhang eine Matrix, die eine dauerelastische wasserhaltige Umhüllung besitzt und die einen Gesamtdurchmesser zwischen 0,3 bis 20 mm aufweist. Verwendung findet diese Matrix insbesondere zur Stärkung der körperlichen und geistigen Leistungsfähigkeit und Belastbarkeit.
PCT/EP2003/004030 2002-04-19 2003-04-17 Matrix mit einer bioaktiven phospholipid-haltigen komponente WO2003088949A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003229693A AU2003229693A1 (en) 2002-04-19 2003-04-17 Matrix comprising a bioactive component containing phospholipid
JP2003585701A JP4599604B2 (ja) 2002-04-19 2003-04-17 生体活性のリン脂質含有成分を含有するマトリックス
US10/511,888 US20050232996A1 (en) 2002-04-19 2003-04-17 Matrix comprising a bioactive component containing phospholipid
EP03722502A EP1503742A2 (de) 2002-04-19 2003-04-17 Matrix mit einer bioaktiven phospholipid-haltigen komponente

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10217558.6 2002-04-19
DE10217558 2002-04-19
DE10250727.9 2002-10-31
DE10250727A DE10250727B4 (de) 2002-04-19 2002-10-31 Matrix mit einer bioaktiven Phospholipid-haltigen Komponente

Publications (2)

Publication Number Publication Date
WO2003088949A2 WO2003088949A2 (de) 2003-10-30
WO2003088949A3 true WO2003088949A3 (de) 2004-12-16

Family

ID=29251774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004030 WO2003088949A2 (de) 2002-04-19 2003-04-17 Matrix mit einer bioaktiven phospholipid-haltigen komponente

Country Status (5)

Country Link
US (1) US20050232996A1 (de)
EP (1) EP1503742A2 (de)
JP (1) JP4599604B2 (de)
AU (1) AU2003229693A1 (de)
WO (1) WO2003088949A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158139A0 (en) 2003-09-25 2004-09-27 Enzymotec Ltd Stabilized formulations of phosphatidyl serine
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
KR20130046451A (ko) * 2005-06-28 2013-05-07 케이지케이 시너자이즈 인코포레이티드 심혈관 질환의 치료를 위한 폴리메톡시플라본 및 토코트리에놀의 생체이용율을 개선시키기 위한 조성물
DE102007042557A1 (de) 2007-09-07 2009-03-19 Membramed Gmbh Neuartige Formulierung von Phospholipiden
EP2847207B1 (de) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Nanokristalle von Fluticasonpropionat
EP3596182B1 (de) 2017-03-17 2021-06-30 Dow Global Technologies LLC Epoxid-acryl-hybridklebstoff
RU2020118504A (ru) * 2017-11-27 2021-12-06 Карджилл, Инкорпорейтед Двойные эмульсии

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011294A1 (en) * 1990-12-20 1992-07-09 Fidia S.P.A. Heparin derivatives
WO1993021190A1 (en) * 1992-04-17 1993-10-28 Fidia S.P.A. Method for the preparation and purification of phospholipid mixtures free from contamination by unconventional viruses
WO2001084961A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212900B (it) * 1983-11-17 1989-11-30 Valle Francesco Della Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5342626A (en) * 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
US6103271A (en) * 1994-12-02 2000-08-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulation and electrostatic processing method
FR2729296B1 (fr) * 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
JPH10330250A (ja) * 1997-06-03 1998-12-15 Toyo Capsule Kk メナテトレノン油性製剤
US6004571A (en) * 1997-09-04 1999-12-21 Thies; Curt Simulated insect eggs
AU1380199A (en) * 1997-12-26 1999-07-19 Warner-Lambert Company Gelatine compositions
DE69917609T2 (de) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao Arzneimittel und deren verwendung
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2001247453A (ja) * 2000-03-09 2001-09-11 Marin Pharm:Kk ソフトカプセル用皮膜及びソフトカプセル剤
CN1446093A (zh) * 2000-04-07 2003-10-01 得克萨斯系统大学董事会 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011294A1 (en) * 1990-12-20 1992-07-09 Fidia S.P.A. Heparin derivatives
WO1993021190A1 (en) * 1992-04-17 1993-10-28 Fidia S.P.A. Method for the preparation and purification of phospholipid mixtures free from contamination by unconventional viruses
WO2001084961A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Also Published As

Publication number Publication date
JP4599604B2 (ja) 2010-12-15
AU2003229693A1 (en) 2003-11-03
AU2003229693A8 (en) 2003-11-03
EP1503742A2 (de) 2005-02-09
US20050232996A1 (en) 2005-10-20
JP2006504628A (ja) 2006-02-09
WO2003088949A2 (de) 2003-10-30

Similar Documents

Publication Publication Date Title
WO2004010987A3 (en) Use of s1p receptor agonists in heart diseases
WO2006031878A3 (en) Imidazoquinoline compounds
WO2004062589A3 (en) An emollient alcohol skin disinfecting formulation
WO2005070183A3 (en) Ice cream and ice cream formulations containing maltitol
WO2003088949A3 (de) Matrix mit einer bioaktiven phospholipid-haltigen komponente
WO2008006514A8 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
WO1999027793A3 (en) An antimicrobial composition
WO2004103407A3 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2004064542A8 (fr) Composition pour une administration par voie orale contenant des capsaicinoïdes
HUP0500127A2 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
WO2006121717A3 (en) Skin care compositions containing idebenone
EP1608395A4 (de) Antikrebsmittel mit lk8-protein als wirkstoff
HUP0004375A2 (hu) Azelainsavat tartalmazó kompozíció
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
WO2003018064A3 (en) Lipophilic drug compositions
AU2001278516A1 (en) Oral cosmetic composition comprising petroleum jelly enrobing an active agent
PL372720A1 (en) Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
IL174691A0 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
WO2004039326A3 (en) Propofol with cysteine
WO2003020963A3 (en) Proteins in type 2 diabetes
WO2004089964A8 (ja) 脂質調節剤及びその用途
AU2002367430A1 (en) Fat and oil compositions for decreasing blood lipid
WO2007027092A3 (en) Oral composition for moisturising skin
WO2003011247A3 (de) Trägermatrix mit wirkstoffbeladenen partikeln zur anwendung auf der haut oder schleimhaut
WO2005039288A3 (en) An insectidcidal composition with enhanced synergistic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10511888

Country of ref document: US

Ref document number: 2003585701

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003722502

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003722502

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642